Harte Hanks Stock Price, News & Analysis

Harte Hanks, Inc. (Nasdaq: HHS) announced it will release its financial results for Q4 ended December 31, 2021, after the market closes on February 24, 2022. A conference call will follow at 4:30 p.m. ET to discuss the results. Interested parties can access the webcast online or via phone. The company specializes in customer experience strategies and analytics, serving clients like Bank of America and Pfizer, with over 2,500 employees in multiple regions.

Harte Hanks (Nasdaq: HHS) has secured a multi-year contract from a national healthcare organization to provide new mothers with essential products, including breast milk pumps and health-related materials. This initiative aligns with the Affordable Care Act's goal to enhance newborn nutrition. Over 100,000 breast milk kits are expected to be delivered in the first year. Harte Hanks was chosen for its comprehensive, cost-effective solutions and established relationship with the client, enabling efficient service delivery.

Harte Hanks (Nasdaq: HHS) announced the launch of an expanded healthcare practice, spearheaded by Janel Harris, an executive with extensive healthcare agency experience. The practice aims to leverage integrated services including patient insights and data analytics, enhancing client engagement in the healthcare sector. The company operates multiple distribution centers, including a new 400,000 square foot facility in Kansas City, fulfilling over 1.3 million packages annually. Harte Hanks continues to cater to major clients like GSK and Pfizer, aiming to provide comprehensive patient-centric solutions.

Harte Hanks (Nasdaq: HHS), a global customer experience company, will present at the Sidoti & Company Virtual Small-Cap Conference on January 20, 2022, at 10 a.m. ET. Management will also hold one-on-one meetings on January 19 and 20, 2022. Interested parties can access the presentation via webcast on the Harte Hanks investor relations website. For meeting requests, participants may contact their Sidoti representative or email hhs@fnkir.com.

Harte Hanks (NASDAQ: HHS) has appointed Don Aicklen as the new Senior Vice President of Sales and Marketing, returning to the company with extensive sales experience. Aicklen previously led Harte Hanks' national sales organization, contributing to significant growth, particularly in automotive and consumer durables. His past leadership at KBM Group and startups in marketing services also highlights his expertise. CEO Brian Linscott praised Aicklen's talent and strategic vision to drive growth initiatives in 2022 and beyond.

Harte Hanks, Inc. (HHS) announced a new $25 million revolving line of credit with Texas Capital Bank on Dec. 21, 2021. This credit facility aims to enhance the company's strategic position and financial flexibility, allowing for working capital, debt repayment, and investment in client offerings. CEO Brian Linscott highlighted the facility's importance for ensuring financial stability and eliminating the need for third-party guarantees, showcasing the success of their turnaround plan.

Harte Hanks, Inc. (OTCQX: HRTH) has announced its approval for listing on the Nasdaq, effective December 1, 2021, where it will trade under the symbol 'HHS'. The company has met stringent financial and corporate governance requirements. This uplisting is viewed as a significant milestone that is expected to enhance liquidity and investor access. Chairman Jack Griffin emphasized the return to a national exchange as a major progress indicator, while CEO Brian Linscott highlighted the potential to expand the institutional shareholder base and increase long-term shareholder value.

Harte Hanks (NYSE: HHS) was notified by the NYSE on July 9, 2020, about the commencement of delisting proceedings due to non-compliance with listing standards, specifically failing to maintain $50 million in stockholders' equity or market capitalization. The company plans to transition to the OTCQX Best Market, where it will trade under the symbol "HRTE." Despite the delisting, Harte Hanks asserts that its business operations will remain unaffected. The NYSE will inform about the suspension date after the review period.

Harte Hanks (NYSE: HHS) has been chosen by Flagship Biosciences to implement a strategic marketing campaign aimed at enhancing customer acquisition. This initiative will encompass a targeted, multi-channel approach, integrating email, digital advertising, and content creation to engage critical decision-makers in the biotechnology sector. The campaign's objective is to showcase Flagship's capabilities in accelerating drug development and improving patient outcomes, leveraging Harte Hanks' expertise in behavioral marketing.